Produktinformation |
Auf dieser Seite finden Sie alle Nachrichten zeitlich geordnet und zu unterschiedlichen Themen der letzten drei Tage aufgelistet. Wählen Sie aus der untenstehenden Tabelle die für Sie interessante Nachricht aus. Zusätzlich können Sie auch unsere Nachrichtensuche nutzen, um damit noch detaillierter nach bestimmten und weiter zurückliegenden Nachrichten zu suchen.
27.03.2025 09:02 Original-Research: INDUS Holding AG (von NuWays AG): BUY ^ Original-Research: INDUS Holding AG - from NuWays AG 27.03.2025 / 09:02 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions. --------------------------------------------------------------------------- Classification of NuWays AG to INDUS Holding AG Company Name: INDUS Holding AG ISIN: DE0006200108 Reason for the research: Update Recommendation: BUY from: 27.03.2025 Target price: EUR 34.00 Target price on sight of: 12 months Last rating change: Analyst: Christian Sandherr Solid FY24 numbers and promising mid-term outlook; chg. Topic: INDUS released solid final FY24 numbers in line with prelims and presented its mid-term targets for 2030 at the CMD in Frankfurt. Here are our key takeaways: To recap, FY24 sales decreased 4.5% yoy to EUR 1,722m due to macroeconomic headwinds especially in the construction industry and pricing pressure in Materials Solutions (former Materials). Q4 sales came in at EUR 440m, flat yoy. Order intake decreased across all segments to EUR 1,611 in total with a book-to-bill of 0.94x and 3.7% below last year due to a persistently weak economy. Consequently, the order backlog decreased 10.4% yoy to a low level of EUR 637m. FY adj. EBITA came in at EUR 154m, -18.3% yoy due to a top-line decrease and higher personnel expenses (+3% yoy) despite 161 fewer employees. This leads to a still solid 8.9% adj. EBITA margin (-1.5ppts) considering the current economic environment. Engineering FY sales remained flat yoy (-0.5%) but adj. EBITA decreased by 21.5% due to an unfavorable product mix in H1. Infrastructure recorded a 3.9% decline in sales, however, with a 2.9% increase in adj. EBITA thanks to a reduction of 7.4% yoy in cost of materials and a positive one-time effect from the sale of a non controlling interest in BETOMAX for EUR 2.6m. Sales in the Materials Solutions segment dropped by 8.9% and adj. EBITA disproportionately by 25.2% yoy due to a weak metals sector and pricing pressure. In particular suppliers of the construction and agricultural industry are currently facing low demand. On a regional sales split, top-line in Germany decreased by 8.2% (48% of total sales), while sales in EU declined by only 4.5% and in third countries even increased by 1.8% yoy. The continued investment reluctance in Germany and a still muted GDP growth forecast of 0.3% for FY25e by the IMF, gave INDUS reason to expand its geographic M&A scope. Growth acquisitions will be expanded to Europe and add-on acquisitions are searched globally with a particular focus on North America. This is positive news in our view, as INDUS will become less dependent on the German economy and can now search more opportunistically in different geographies for value accretive M&A targets. Ambitious mid-term target: Management aims for sales of EUR 3bn and adj. EBITA of EUR 330m until FY30e, not factoring in any potential impact of Germany's EUR 500bn infrastructure special fund. EUR 700m additional sales are expected to come from organic growth (implied 5.9% CAGR) and EUR 600m from acquisitions, for which the company plans to spend approximately EUR 500m. INDUS sees a huge market potential for succession solutions in Europe. Around 90% of family businesses in Europe see an external investor as a suitable succession option and long-term oriented investors such as INDUS who preserve the DNA of the target business are often preferred by Mittelstand companies. Although we believe the targeted 11% adj. EBITA margin is well in reach, we take a more conservative view on organic top-line growth. Thus, we estimate INDUS to reach c. EUR 500m organic sales growth until FY30e (implied 4.3% CAGR). FY25e guidance in reach: INDUS expects sales between EUR 1.75-1.85bn (eNuW: EUR 1.79bn) and adj. EBITA in the range of EUR 150-175m (eNuW: EUR 164m) for the current year. Although a yoy decline in backlog, the guidance looks plausible in our view supported by EUR 28m annualized sales contribution from INDUS' acquisitions since the start of the year. Further, the acquisitions made in FY24 have an annualized sales contribution of c. EUR 35m (vs. EUR 18.4m recorded sales in FY24). We reiterate BUY with unchanged PT of EUR 34, based on FCFY25e. You can download the research here: http://www.more-ir.de/d/32072.pdf For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++ --------------------------------------------------------------------------- The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com --------------------------------------------------------------------------- 2107200 27.03.2025 CET/CEST ° Weitere Nachrichten |
Name | Kurs | Währung | Datum | Zeit | Handelsplatz |
---|---|---|---|---|---|
INDUS HOLDING AG | 24,650 | EUR | 01.04.25 | 17:35 | Xetra |
|
Lesen Sie auch weitere interessante Nachrichten u.a. zu den Themen Aktien im Fokus, Hintergrundberichte, Börsentag auf einem Blick, Wochenausblick oder adhoc-Mitteilungen. |
02.04.2025 WINDTREE THERAPEUTICS Geschäftsbericht VONTOBEL HOLDING AG Analysten-, Investoren- & Aktionärskonferenzen TWO HANDS CORPORATION Geschäftsbericht TRINITY BIOTECH Geschäftsbericht Übersicht |